AGP Executive Report
Last update: 4 hours agoBiopharma Deals: Viatris agreed to acquire Pacira BioSciences for $1.65 billion, adding its non-opioid pain medicines Exparel and Zilretta. Drug Manufacturing: Tonix broke ground on a Hamilton, Montana, facility that will initially make its Lyme disease prevention candidate; Bio-Techne also opened a UK GMP plant to support cell-therapy development. AI Oversight: The UK government accepted all 44 recommendations for regulating AI in healthcare, with a delivery roadmap due in spring 2027. Drug Pricing: New York’s attorney general secured $1 million from Ascend Laboratories and Mayne Pharma over alleged generic-drug price fixing; eligible consumers may seek compensation. Insurance Competition: Michigan sued Blue Cross Blue Shield of Michigan, alleging an illegal monopoly that inflated costs. Patient Costs: Cash-pay drug deals may not count toward insurance deductibles or out-of-pocket limits, potentially leaving patients with higher costs later. Care Integration: UK physicians are being urged to make oral health part of routine care, as dental problems can affect broader health and remain difficult to treat.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
